Screener
Kymera Therapeutics KYMR Other Nonoperating Income
Other Nonoperating Income at other companies
Other financials
Where this comes from
Reported directly by Kymera Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OtherNonoperatingIncome.
The source filing: Kymera Therapeutics’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 7:15 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-333849
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Total operating expenses | 140,607 | 96,033 | 259,128 | 192,559 |
| Loss from operations | (75,607) | (84,557) | (159,763) | (158,983) |
| Other income (expense): | ||||
| Interest and other income | 14,477 | 8,051 | 29,459 | 16,968 |
| Interest and other expense | (81) | (108) | (141) | (180) |
| Total other income: | 14,396 | 7,943 | 29,318 | 16,788 |
| Net loss | $(61,211) | $(76,614) | $(130,445) | $(142,195) |
| Other comprehensive loss: |
Item 1. Financial Statements.
FAQ
- What is Kymera Therapeutics's other nonoperating income?
- Kymera Therapeutics (KYMR) reported other nonoperating income of $14.48M in Q2 2026.
- How has Kymera Therapeutics's other nonoperating income changed year-over-year?
- Kymera Therapeutics's other nonoperating income increased by 79.8% year-over-year, from $8.05M to $14.48M.
- What is the long-term trend for Kymera Therapeutics's other nonoperating income?
- Over 4 years (2021 to 2025), Kymera Therapeutics's other nonoperating income has grown at a 198.2% compound annual growth rate (CAGR), from $486K to $38.42M.
- What does other nonoperating income mean?
- Other Nonoperating Income as reported by Kymera Therapeutics, Inc. Common Stock.
Ask your AI about Kymera Therapeutics's other nonoperating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude